Hemophilia firm from former Novo employee secures millions from Novo Seeds
Following 12 years at Novo Nordisk, Johan Faber broke out last year to found the biotech firm Hemab, which will develop drugs against rare haemophilia diseases. The firm has just landed a two-digit million kroner investment from Novo Seeds.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN
A pile of money has been laid on the table belonging to the newly-founded biotech company Hemab, which develops pharmaceutical drugs against rare bleeding disorders for a market which is estimated to bring in billions of kroner.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
